Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

NCT05627245 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05627245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05627245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 1, 2023
Completion date
June 1, 2027
Enrollment
48 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma germinal center b-cell type, recurrent follicular lymphoma, recurrent non-hodgkin lymphoma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, recurrent transformed non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma germinal center b-cell type, refractory follicular lymphoma, refractory non-hodgkin lymphoma, refractory primary cutaneous t-cell non-hodgkin lymphoma, refractory t-cell non-hodgkin lymphoma, refractory transformed non-hodgkin lymphoma